Skip to main content

ORIGINAL RESEARCH article

Front. Genet.
Sec. Cancer Genetics and Oncogenomics
Volume 15 - 2024 | doi: 10.3389/fgene.2024.1408000
This article is part of the Research Topic Immunotherapy and Biomarkers for Lung Cancer View all 5 articles

A scoring model based on bacterial lipopolysaccharide-related genes to predict prognosis in NSCLC

Provisionally accepted
Nandi Bao Nandi Bao 1*Xinxin Zhang Xinxin Zhang 2Chenyu Lin Chenyu Lin 2Feng Qiu Feng Qiu 3Guoxin Mo Guoxin Mo 2
  • 1 Department of Cardiology, Sixth Medical Center of PLA General Hospital, Beijing, China
  • 2 Department of Pulmonary and Critical Care Medicine, Eighth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, Beijing Municipality, China
  • 3 Department of Neurology, Chinese PLA General Hospital, Beijing, Beijing Municipality, China

The final, formatted version of the article will be published soon.

    Non-small cell lung cancer (NSCLC) has high incidence and mortality rates. The discovery of an effective biomarker for predicting prognosis and treatment response in patients with NSCLC is of great significance. Bacterial lipopolysaccharide-related genes (LRGs) play a critical role in tumor development and the formation of an immunosuppressive microenvironment; however, their relevance in NSCLC prognosis and immune features is yet to be discovered. Methods: Differentially expressed LRGs associated with NSCLC prognosis were identified in the TCGA dataset. Prognostic LRG scoring and nomogram models were established using single-variable Cox regression, Least Absolute Shrinkage, and Selection Operator (LASSO) regression. The prognostic value of the scoring and nomogram models was evaluated using Kaplan-Meier (KM) analysis and further validated using an external dataset. Patients were stratified into high-and low-risk groups based on the nomogram score, and drug sensitivity analysis was performed. Additionally, clinical Conclusions:The LRGs scoring model can serve as a biomarker that contributes to the establishment of a reliable prognostic risk-prediction model, potentially facilitating the development of personalized treatment strategies for patients with NSCLC.

    Keywords: Non-small cell lung cancer, Lipopolysaccharide-related genes, prognosis, Therapeutic response, tumor immune environment, risk score

    Received: 27 Mar 2024; Accepted: 04 Nov 2024.

    Copyright: © 2024 Bao, Zhang, Lin, Qiu and Mo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Nandi Bao, Department of Cardiology, Sixth Medical Center of PLA General Hospital, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.